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AbstrAct:
Since angiogenesis is critical for tumor growth and metastasis, anti-angiogenic 
treatment is a highly promising therapeutic approach. Thus, for over last couple 
of decades, there has been a robust activity aimed towards the discovery 
of angiogenesis inhibitors. More than forty anti-angiogenic drugs are being 
tested in clinical trials all over the world. This review discusses agents that 
have been approved by FDA and are currently in use for treating patients 
either as single-agents or in combination with other chemotherapeutic agents.
WHAt Is ANGIOGENEsIs?
The process of formation of new blood vessels from 
pre-existing blood vessels is termed as angiogenesis. In 
normal physiology, angiogenesis is necessary for repair 
and healing of tissues. Classically, there are sub-types 
of angiogenesis e.g., Sprouting angiogenesis which 
involves stimulation of endothelial cells to proliferate 
into the surrounding matrix and form solid sprouts 
extending towards the angiogenic stimulus leading to the 
formation of an entirely new vessel [1, 2]; Intussusception 
or splitting angiogenesis which involves division of the 
lumen of an existing vessel resulting in formation two 
vessels [3, 4]; Vasculogenesis, which is the formation of 
vasculature from endothelial stem cells or angioblasts, 
which proliferate into de-novo endothelial cells [5]. 
However, from the cancer biology perspective, 
angiogenesis is one of the most critical steps in the 
hematogenous metastasis as it provides the escape route 
for the tumor cells from the confines of the primary tumor 
and allows their seeding in distant organs [6]. 
tUMOr ANGIOGENEsIs 
Some of the early classic experiments have 
demonstrated that tumor angiogenesis is indispensable 
for the growth of solid tumors [7, 8]. Tumor angiogenesis 
is generation of a network of blood vessels within the 
cancerous growth. This process can occur two ways: The 
more accepted model involves the release of signaling 
molecules by the tumor cells; these molecules activate 
the surrounding tissue to promote growth of new blood 
vessels. This stimulates vascular endothelial cells to 
divide rapidly [9, 10]. The other model proposes the 
generation of new vasculature by vasculogenic mimicry. 
This model argues that the tumor cells trans-differentiate 
in endothelial-like cells and create structures from inside 
of the tumor tapping into a nearby blood vessel [4].
ANGIOGENEsIs AND MEtAstAsIs
Escape of the tumor cell from the confines of the 
primary tumor to distant body parts is the pre-requisite for 
hematogenous metastasis. This escape route is provided 
by the tumor vasculature. Thus, it was envisioned that 
inhibition of angiogenesis will also lead to inhibition of 
metastasis. This phenomenon was demonstrated by very 
elegant mouse model studies using angiostatin [11, 12]. 
Angiostatin was also demonstrated to be secreted by 
some primary tumors leading to restricted growth of the 
metastasis leading to “dormancy” of the metastasis. Mice 
deficient in angiogenesis (Id1 & Id3 deficient) showed 
significantly  less  tumor  take  rates  [13].  Independent 
studies showed absence of metastasis in angiogenesis 
deficient  mice  [14,  15].  Defective  angiogenesis  was 
attributed to impaired VEGF-dependent recruitment of 
precursor endothelial cells from the bone marrow to the 
newly developing tumor vasculature [16].
LYMPHANGIOGENEsIs 
Metastasis of malignant tumors to regional lymph Oncotarget 2011; 2:  122 - 134 123 www.impactjournals.com/oncotarget
nodes is one of the early signs of cancer spread in patients, 
and it occurs at least as frequently as hematogenous 
metastasis [17]. Particularly, in cancers, such as breast 
cancer, lymphatic metastasis is a predominant route for 
tumor spread. The contribution of lymphatic system to 
the tumor growth is an area that is relatively less studied. 
However, lymphatic vessels are speculated to contribute 
to tumor growth and metastasis in a variety of ways. The 
VEGF, FGF2 and PDGF produced by vascular endothelial 
cells are proposed to be involved in the activation of 
lymphatic endothelial cells, which in turn produce matrix 
metalloproteases and urokinase plasminogen activator 
(uPA) that can promote malignant tumor growth. Thus, 
there exists a synergistic crosstalk between the tumor and 
the lymphatic vessels and blood vessels. 
rEGULAtOrs OF tUMOr 
ANGIOGENEsIs
Angiogenesis is a complex and intricately regulated 
process. Like all other regulated biological phenomena, 
angiogenesis has activators or pro-angiogenic factors and 
inhibitors or anti-angiogenic factors [9]. 
the Activators
Tumor cells activate signaling pathways that promote 
uncontrolled proliferation and survival. These include the 
PI3K/AKT/mTOR pathway, Hedgehog pathway and, Wnt 
pathway [18-24] that produce pro-angiogenic signaling 
intermediates [25, 26]. Among the several reported 
activators of angiogenesis present in cells two proteins 
appear to be the most important for sustaining tumor 
growth: vascular endothelial growth factor (VEGF) and 
basic fibroblast growth factor (bFGF). VEGF and bFGF 
are secreted by the tumor into the surrounding tissue. 
They bind to their cognate receptors on endothelial cells. 
This activates a signaling cascade that transmits a nuclear 
signal prompting target genes to activate endothelial cell 
growth. Activated endothelial cells also produce matrix 
metalloproteinases (MMPs). These MMPs break down the 
extracellular matrix and allow the migration of endothelial 
cells. The division and migration of the endothelial cells 
leads to formation of new blood vessels [27, 28]. 
the Inhibitors
If angiogenesis is so critical for the tumor growth, 
targets of FDA-approved angiogenesis inhibitors: Angiogenesis inhibitors impact both, the tumor as well as the endothelial 
cells resulting in the disruption of the effects of the microenvironment in promoting tumor growth and angiogenesis. Tumor 
cells produce pro-angiogenic agents including VEGF, bFGF and TGF-α by the signaling pathways such as Hh pathway (19) as well as their 
intermediates including oncoproteins such as COX-2 and osteopontin (25, 26). These factors signal and activate endothelial cells that produce 
proteases such as MMPs that facilitate invasive properties of the tumor cells. Bevacizumab binds to and squelches the availability of VEGF. 
Cetuximab and Panitumumab inhibit the activities of VEGF receptor ( ). Tumor cells themselves are negatively impacted by Trastuzumab 
that deprives the effects of HER-2. Small molecule tyrosine kinase inhibitors such as Erlotinib, Sorafenib and Sunitinib block the activity 
of multiple growth factor receptors ( ) including VEGF receptors, PDGF-receptors, RET and Raf-1. Rapamycin targets mTOR. The exact 
molecular targets of other agents including thalidomide and Bortezomib are not fully understood.
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then agents that inhibit angiogenesis would have great 
therapeutic value. With the discovery of endostatin, the 
concept of anti-angiogenic therapy was launched and 
popularized by Dr. Folkman [29]. Angiogenesis inhibitors 
have been discovered from a variety of sources. Some are 
naturally present in the human body e.g. specific fragments 
of structural proteins such as collagen or plasminogen 
(angiostatin, endostatin, tumstatin) [30]. Others are natural 
products in green tea, soy beans, fungi, mushrooms, tree 
bark, shark tissues, snake venom etc. [31]. A plethora of 
synthetic compounds are also characterized to have anti-
angiogenic properties [32]. 
ANtI-ANGIOGENIc trEAtEMENt OF 
cANcEr
Since angiogenesis is an event critical to primary 
tumor growth as well as metastasis, anti-angiogenic 
treatment of tumors is a highly promising therapeutic 
avenue [33]. Thus, for over last couple of decades, there 
has been a robust activity aimed towards the discovery 
of angiogenesis inhibitors [34, 35]. More than forty 
anti-angiogenic drugs are being tested in human cancer 
patients in clinical trials all over the world. From the 
several anti-angiogenic agents reported, we have focused 
this review on discussing those agents that have received 
FDA approval in the United States and are currently in 
use for treating patients either as a single-agent or in 
combination with other chemotherapeutic agents (Figure 
1). Based on functionality, the anti-angiogenic drugs can 
be sub-divided into three main groups:
Drugs that inhibit growth of endothelial cells
e.g. Endostatin and combretastatin A4, cause 
apoptosis of the endothelial cells [36]. Thalidomide is also 
a potent inhibitor of endothelial cell growth [37].
Drugs that block angiogenesis signaling
e.g. anti-VEGF antibodies (Avastin, FDA approved 
for  colorectal  cancer),  Interferon-alpha  (inhibits  the 
production of bFGF and VEGF) [36].
Drugs that block extracellular matrix breakdown
e.g. inhibitors of MMPs [38].
ANtI-ANGIOGENIc tHErAPIEs tHAt 
HAVE rEcEIVED UsA-FDA APPrOVAL
Conventional chemotherapy is usually a systemic 
therapy that tries to capture a narrow therapeutic window 
offered by rapid proliferation of tumor cells compared 
to the normal cells. Chemotherapy has significant side 
effects such as hair loss, diarrhea, mouth ulcer, infection, 
and low blood counts. Anti-angiogenic therapy has several 
advantages over chemotherapy as it is mostly not directed 
towards directly killing cells but stopping the blood 
vessel formation, an event that is rare in tissues other than 
growing tumor. Hence it is well tolerated by the patients 
and has fewer side effects [29]. There are currently seven 
approved anti-cancer therapies in two primary categories: 
1. Monoclonal antibodies directed against specific 
pro-angiogenic growth factors and/or their receptors
2. Small molecule tyrosine kinase inhibitors (TKIs) 
of multiple pro-angiogenic growth factor receptors. 
Besides  these,  inhibitors  of  mTOR  (mammalian 
target  of  rapamycin),  proteasome  inhibitors  and 
thalidomide have also been reported to indirectly inhibit 
angiogenesis through mechanisms that are not completely 
understood. 
MONOcLONAL ANtIbODY tHErAPIEs
Four monoclonal antibody therapies are approved to 
treat several tumor types: 
bevacizumab (Avastin®)
The  first  FDA  approved  angiogenesis  inhibitor, 
Avastin is a humanized monoclonal antibody that 
binds biologically active forms of vascular endothelial 
growth factor (VEGF) and prevents its interaction with 
VEGF  receptors  (VEGFR-1  and  VEGFR-2),  thereby 
inhibiting endothelial cell proliferation and angiogenesis. 
Bevacizumab has been tested in phase I studies in 
combination with chemotherapy with a good safety 
profile  [39].  This  treatment  is  approved  for  metastatic 
colorectal cancer and non-small cell lung cancer [40-43]. 
Bevacizumab has also evolved as a first line of treatment 
in combination with paclitaxel in breast cancer patients 
by virtue of its ability to double median progression-free 
survival (PFS) [44]. In combination with chemoendocrine 
therapy  (including  capecitabine  and  vinorelbine,  and 
letrozole) bevacizumab treatment significantly decreased 
the percentage of viable circulating endothelial cells 
and prevented the chemotherapy-induced mobilization 
of circulating progenitors [45]. In combination with 
irinotecan,  bevacizumab  significantly  increased  PFS 
in glioma patients [46, 47]. VEGF has emerged as a 
compelling therapeutic target for leukemias. Inhibition 
of angiogenesis in hematological malignancies interdicts 
the angiogenesis within the bone marrow ecosystem 
comprised  of  multiple  cell  types,  including  fibroblasts, 
endothelial progenitor cells, endothelial cells, dendritic 
cells and, malignant cells, blocking the availability of 
nutrients to cancer cells and disrupting crosstalk between 
the various cell types to curtail the malignant phenotype Oncotarget 2011; 2:  122 - 134 125 www.impactjournals.com/oncotarget
[48].
cetuximab (Erbitux®)
This is a monoclonal antibody that binds the 
extracellular domain of epidermal growth factor receptor 
(EGFR), preventing ligand binding and activation of the 
receptor resulting in internalization and degradation of 
the receptor culminating in inhibition of cell proliferation 
and angiogenesis. Cetuximab  downregulated VEGF 
expression  in a dose-dependent manner in a human 
colorectal carcinoma (CRC) cell line and in human CRC 
mouse xenografts [49]. The xenografts also showed a 
significant reduction in blood vessel counts following 
several rounds of cetuximab treatment [49], indicating 
that the tumor-promoting effects of EGFR overexpression 
may be mediated through VEGF stimulation and tumor 
angiogenesis. This treatment is approved for metastatic 
CRC and head and neck cancer [50] in patients who 
are refractory to irinotecan-based chemotherapy. In 
combination with irinotecan (an inhibitor of topoisomerase 
I), cetuximab is the first monoclonal antibody that has 
been  approved  by  the  FDA  as  second-line  treatment 
for metastatic colorectal cancer [51, 52]. In Phase I and 
Phase III trials [53, 54] cetuximab significantly improved 
the effects of radiotherapy in patients with unresectable 
(cannot be removed by surgery) squamous cell carcinoma 
of the head and neck (SCCHN). Cetuximab has also been 
shown to sensitize cells to radiation and chemotherapy, 
potentially through blocking EGFR nuclear import and 
the associated activation of DNA protein kinase enzymes 
necessary for repairing radiation- and chemotherapy-
induced DNA damage [55]. Compared to radiation alone, 
cetuximab plus radiation therapy can nearly double the 
median survival in patients with a certain kind of head and 
neck cancer that has not spread to other parts of the body 
[54] making cetuximab the only drug achieving interesting 
response rate in second line treatment of advanced 
SCCHN [56]. Cetuximab was also found to be tolerated 
well in combination with cisplatin, or carboplatin, and 
fluorouracil [57, 58].
Panitumumab (Vectibix™)
It is a fully humanized anti-EGFR monoclonal 
antibody  that  binds  specifically  to  the  human  EGFR. 
Panitumumab is a recombinant human monoclonal 
antibody [59]; therefore, the risk of an infusion reaction 
is minimized. Vectibix® is indicated as a single agent for 
the treatment of EGFR-expressing, metastatic colorectal 
carcinoma with disease progression on or following 
fluoropyrimidine-, oxaliplatin-, and irinotecan-containing 
chemotherapy regimens [60-62]. The effectiveness of 
Vectibix® as a single agent for the treatment of EGFR-
expressing, metastatic CRC is based on progression-free 
survival [63, 64]. Panitumumab is used in patients who 
are not responding to regimens containing fluorouracil, 
oxaliplatin, and irinotecan [60]. Patients often receive 
panitumumab after receiving bevacizumab or cetuximab. 
Panitumumab can be given with FOLFOX (oxaliplatin, 
leucovorin,  and  fluorouracil)  or  FOLFIRI  (irinotecan, 
leucovorin,  and  fluorouracil)  regimens,  or  as  a  single 
agent. Currently no data are available that demonstrate an 
improvement in disease-related symptoms or increased 
survival with Vectibix® in colon cancer [65]. This drug 
is also being tested for aerodigestive track and head and 
neck cancer [66, 67].  
trastuzumab (Herceptin®)
Is a humanized monoclonal antibody that binds the 
extracellular domain of HER-2, which is overexpressed 
in 25-30% of invasive breast cancer tumors [68]. HER2-
positive breast cancer is highly aggressive disease with 
high recurrence rate, poorer prognosis with decreased 
survival compared with HER2-negative breast cancer 
[69]. Herceptin® is designed to target and block the 
function of HER2 protein overexpression. This is the 
first humanized antibody is approved for Breast cancer 
[70]. Herceptin® is approved by the FDA to treat HER2 
positive breast cancer that has metastasized after treatment 
with other anticancer drugs [71]. It is also approved to 
be used with other drugs to treat HER2-positive breast 
cancer that has spread to the lymph nodes to be used after 
surgery. The FDA first approved Herceptin in September 
1998  [71-73].  In  November  2006,  the  FDA  approved 
Herceptin as part of a treatment regimen containing 
doxorubicin, cyclophosphamide and paclitaxel, for the 
adjuvant treatment of patients with HER2-positive, node-
positive breast cancer (http://www.fda.gov/NewsEvents/
Newsroom/PressAnnouncements/default.htm).  In 
January 2008, the FDA approved Herceptin as a single 
agent for the adjuvant treatment of HER2-overexpressing 
node-negative  (ER/PR-negative  or  with  one  high-
risk  feature)  or  node-positive  breast  cancer,  following 
multi-modality  anthracycline-based  therapy  (http://
biopharminternational.findpharma.com/biopharm/News/
FDA-Approves-Expanded-Adjuvant-Indications-for-Her/
ArticleStandard/Article/detail/518867).  Trastuzumab 
is also being studied in the treatment of other types of 
cancers such as pancreatic [74], endometrial [75], lung 
[76], cervical [77] and ovarian cancer [78]
sMALL MOLEcULE tYrOsINE KINAsE 
INHIbItOrs (tKIs)
Protein tyrosine kinases have emerged as crucial 
targets for therapeutic intervention in cancer especially 
because they play an important role in the modulation of 
growth factor signaling. As per ClinicalTrials.gov (www.Oncotarget 2011; 2:  122 - 134 126 www.impactjournals.com/oncotarget
clinicaltrials.gov), there are 43 ongoing studies on tyrosine 
kinase inhibitors in angiogenesis. Since discussing all of 
them is beyond the scope of this article, we have focused 
our discussion on the three TKIs that are currently 
approved as anti-cancer therapies:
Erlotinib (tarceva®)
Erlotinib  hydrochloride  (originally  coded  as  OSI-
774)  is  an  orally  available,  potent,  reversible,  and 
selective inhibitor of the EGFR (ErbB1) tyrosine kinase 
activity. Erlotinib hydrochloride has been approved by 
FDA  for  treatment  of  patients  with  locally  advanced 
or metastatic NSCLC after failure of at least one prior 
chemotherapy regimen [79, 80]. Interesting recent studies 
have demonstrated that since Erlotinib and Bevacizumab 
act on two different pathways critical to tumor growth and 
dissemination, administering these drugs concomitantly 
may confer additional clinical benefits to cancer patients 
with advanced disease. This combination therapy may 
prove to be a viable second-line alternative to chemotherapy 
in  patients  with  NSCLC  [81].  Also,  for  patients  with 
locally advanced, unresectable or metastatic pancreatic 
carcinoma, Erlotinib has received FDA approval for the 
treatment in combination with gemcitabine [82, 83]. 
Erlotinib is also being studied in the treatment of other 
types of cancers. For example combination of Erlotinib 
with Bevacizumab has been evaluated in metastatic 
breast cancer [84], hepatocellular carcinoma [85] and in 
metastatic renal cancer [86] as phase II trials. Outcomes 
for prostate, cervical and colorectal cancers treated with 
Erlotinib are cautiously optimistic [87-89]. 
sorafenib (Nexavar®)
Sorafenib is an orally active inhibitor of VEGFR-1, 
VEGFR-2,  VEGFR-3,  PDGFR-ß,  and  Raf-1  tyrosine 
kinase activity [90]. It has received the approval of FDA for 
the treatment of patients with unresectable hepatocellular 
carcinoma [91] and advanced renal cell carcinoma [92]. 
However, not all advanced hepatocellular carcinoma 
patients were able to tolerate sorafenib and some patients 
experienced tumor progression [91]. Sorafenib has shown 
improvements in PFS in patients with renal cell carcinoma 
[93]. It is one of the aggressively studied drugs. According 
to the NCI clinical trials search results, there are about 
168 active clinical trials involving sorafenib in a variety 
of cancers.
sunitinib (sutent®)
Sunitinib targets activity of multiple tyrosine kinases 
such as VEGFR-1, VEGFR-2, VEGFR-3, PDGFR- ß, and 
RET [94]. It is approved by FDA as Sunitinib malate for 
treating advanced (metastatic) renal cell carcinoma [95]. It 
is also approved by FDA for gastrointestinal stromal tumor 
(GIST) in patients whose disease has progressed or who 
are unable to tolerate treatment with imatinib (Gleevec), 
the current treatment for GIST patients [95, 96]. Sunitinib 
has shown early evidence of anti-tumor activity in Phase 
II trials in US, European and Asian patients with locally 
advanced, unresectable and metastatic hepatocellular 
carcinoma. A Phase III trial of sunitinib in hepatocellular 
carcinoma is ongoing [97]. According to the NCI clinical 
trials search results, Sunitinib is currently evaluated in 
about 150 active clinical trials. It is evaluated for ovarian 
[98], breast [99] and non small cell lung cancer [100] 
among others [101]. 
Inhibitors of mtOr
mTOR plays a part in the PI3 kinase/AKT pathway 
involved in tumor cell proliferation and angiogenesis 
[102]. Rapamycin and related mTOR inhibitors inhibit 
endothelial cell VEGF expression, as well as VEGF-
induced endothelial cell proliferation [103]. Inhibitors of 
mTOR are an important class of anti-angiogenic agents. 
These include: deforolimus, everolimus, rapamycin 
(sirolimus), and temsirolimus [104, 105]. Temsirolimus 
(Toricel™)  is  a  small  molecule  inhibitor  of  mTOR, 
approved for treating advanced renal cell carcinoma 
[106]. It is a type of rapamycin analog and a type of serine/
threonine kinase inhibitor, it is also called CCI-779. In pre-
clinical models combination therapy for treating breast 
cancer using anti-estrogen, ERA-923, and temsirolimus 
has been successfully tested [107]. It is found to be 
highly effective against human melanoma when tested 
in combination with cisplatin and DTIC (in independent 
studies) in a SCID mouse xenotranplantation model [108, 
109]. There are over 41 active studies of Temsirolimus for 
a variety of solid tumors [110]. mTOR inhibition has also 
been strongly advocated in as a putative cancer therapeutic 
strategy for urologic malignancies [111]. In a pilot study (6 
patients) with imatinib-resistant CML, rapamycin induced 
major and minor leukocyte responses, with an observed 
decrease in the mRNA levels of VEGFA in circulating 
leukaemic cells [112]. Combination treatments for breast 
cancer with aromatase inhibitor [113] and letrozol [114] 
are also being evaluated. Rapamycin treatment brought 
partial responses (>50% reduction in the absolute number 
of  blood  blasts)  and  stable  disease  in  adult  refractory/
relapsed AML [115]. In a recent report, Deforolimus was 
studied in a Phase 2 trial in pretreated patients with various 
hematological malignancies, including ALL, AML, CLL, 
CML,  MDS,  agnogenic  myeloid  metaplasia,  mantle 
cell lymphoma and T-cell leukemia/lymphoma [116]. 
Overall, 40% of deforolimus-treated patients experienced 
hematological improvement or stable disease.Oncotarget 2011; 2:  122 - 134 127 www.impactjournals.com/oncotarget
OtHEr ANGIOGENIc AGENts
bortezomib (Velcade®)
Is a proteasome inhibitor that disrupts signaling of 
cancer cells, leading to cell death and tumor regression. 
It is the first compound in its class to be used in clinical 
practice. It has indirect anti-angiogenic properties [117]. 
While its exact mechanism is not understood, it induces 
the pro-apoptotic BH3-only family member NOXA in a 
p53 independent fashion triggering of a caspase cascade 
culminating in apoptosis in melanoma and myeloma cells 
[118]. It is FDA-approved for the treatment of myeloma 
that  has  relapsed  after  two  prior  treatments  (or  where 
resistance  has  developed  following  the  last  treatment). 
It was also found to induce high quality responses as 
third line salvage therapy with acceptable toxicity in 
a  significant  proportion  of  homogeneously  pre-treated 
myeloma patients with progressive disease after autologous 
transplantation and thalidomide. [119]. In a Phase 3 trial 
involving 669 myeloma patients treated with at least one 
prior therapy, bortezomib increased median, improved 
overall survival, and increased response rate, compared 
with high-dose dexamethasone [120]. In combination 
with doxorubicin and gemcitabine, bortezomib was also 
found to be effective in heavily pretreated, advanced 
Cutaneous T cell Lymphomas (CTCL) [121]. Bortezomib 
was also reported to be active as a single agent for patients 
with relapsed/refractory CTCL and Peripheral T Cell 
Lymphoma (PTCL) with skin involvement [122]. On the 
contrary, the use of bortezomib was discouraged after a 
phase II study revealed that found in combination with 
dexamethasone, bortezomib is not active in heavily pre-
treated patients with relapsed Hodgkin’s lymphoma [123, 
124]. 
thalidomide (thalomid®)
Possesses  immunomodulatory,  anti-inflammatory, 
and anti-angiogenic properties, although the precise 
mechanisms of action are not fully understood. 
Thalidomide  was  the  first  angiogenesis  inhibitor  to 
demonstrate clinical efficacy in multiple myeloma [37, 
125].  Specifically  in  myeloma,  thalidomide  down-
regulated VEGF secretion from bone marrow endothelial 
cells obtained from patients with active disease. In a 
landmark Phase 2 clinical trial, 169 previously treated 
patients with refractory myeloma received thalidomide 
monotherapy [126]. Partial response, was achieved 
in 30% of patients, and 14% achieved a complete or 
nearly complete remission. The survival rate at 2 years 
was 48%. These results led to many subsequent clinical 
studies of thalidomide in myeloma, leading ultimately to 
FDA approval of the drug in 2006, for the treatment of 
newly diagnosed multiple myeloma, in combination with 
dexamethasone. In the pivotal Phase 3 trial, the response 
rate in patients receiving thalidomide plus dexamethasone 
was 63% compared to 41% with dexamethasone alone 
[127]. Long-term outcome measures, including time-
to-progression  (TTP)  and  PFS,  were  recently  reported 
for a 470 patient randomized, placebo-controlled Phase 
3 clinical trial of a similar protocol in newly diagnosed 
multiple myeloma, with comparable overall response rates 
[128]. Significant increases resulted in both median TTP 
and median PFS for the thalidomide plus dexamethasone 
group versus dexamethasone alone. 
Thalidomide was found to be moderately tolerated 
and minimally effective in patients with histologically 
proven advanced hepatocellular carcinoma [129]. 
Thalidomide provided no survival benefit for patients with 
multiple, large, or midbrain metastases when combined 
with WBRT (whole-brain radiation therapy) [130]. On 
the contrary, thalidomide did not significantly add 
to  the  efficacy  of  the  fludarabine, carboplatin, and 
topotecan (FCT) regimen in poor prognosis AML patients 
[131] and was also ineffective in improving prognosis 
or decreasing plasma VEGF levels in patients with 
persistent or recurrent leiomyosarcoma of the uterus [132].
MEtrONOMIc tHErAPY
While conventional anti-angiogenic therapy is based 
on Maximum Tolerated Doses (MTD), the cells involved 
in angiogenesis may regenerate during the three- to 
four-week interval between cycles of the chemotherapy. 
Taking advantage of the fact that endothelial cells are 
about 10–100 times more susceptible to chemotherapeutic 
agents than cancer cells, therapy based on daily, oral, low-
dose chemotherapeutic drugs was designed. Metronomic 
chemotherapy refers to the close, rhythmic administration 
of low doses of cytotoxic drugs, with minimal or no 
drug-free breaks, over prolonged periods. Metronomic 
therapy appears promising mainly due to the fact that 
its anti-angiogenic and anti-tumorigenic effects are 
accompanied by low toxicity, limited side effects, no need 
for hospitalization and allowing for feasible combinations 
with selective inhibitors of angiogenesis. There are several 
foreseeable advantages and opportunities for metronomic 
chemotherapy: activity against the parenchymal and 
stromal components, pro-apoptotic activity, reduction 
of the likelihood of emergence of acquired resistance, 
feasibility of long term administration and acceptable 
systemic side effects [133]. In a pilot phase II study 
conducted by Correale et al [134] to investigate the toxicity 
and activity of the novel metronomic regimen of weekly 
cisplatin and oral etoposide in high-risk patients with 
NSCLC, the objective response rate was 45.2%, disease 
control was 58.1%, meantime to progression and survival 
were 9 and 13 months, respectively. Pharmacokinetic Oncotarget 2011; 2:  122 - 134 128 www.impactjournals.com/oncotarget
analysis showed that this regimen allowed a greater 
median monthly area under the curve of the drugs than 
conventional schedules. In a Phase I trial of metronomic 
dosing of docetaxel and thalidomide, of the 26 patients 
with advanced tumors enrolled, prolonged freedom 
from disease progression was observed in 44.4% of the 
evaluable patients [135].
Circulating  endothelial  progenitor  cells  (EPCs) 
also participate in tumor angiogenesis. In a study 
comparing the effects of metronomic chemotherapy over 
conventional dose-dense chemotherapy, it was found that 
the numbers of circulating EPCs and the plasma levels of 
VEGF increased sharply, doubling pre-therapeutic levels 
at day 21 after conventional chemotherapy, whereas 
under low-dose metronomic chemotherapy, the numbers 
of  circulating  EPCs  decreased  significantly  and VEGF 
plasma concentrations remained unchanged. These 
observations provide evidence that conventional dose-
dense chemotherapy leads to rebound EPC mobilization 
even when given with adjuvant intention, while low-dose 
metronomic scheduling of cytotoxic substances such as 
trofosfamide may sharply reduce EPC release into the 
circulation. [136].
Combined bevacizumab and metronomic oral 
cyclophosphamide was also discovered to be a safe and 
effective regimen for heavily pre-treated ovarian cancer 
patients [137]. Treatment with metronomic capecitabine 
and cyclophosphamide in combination with bevacizumab 
was shown to be effective in advanced breast cancer and 
additionally was minimally toxic [138].  Metronomic 
treatment with carboplatin and vincristine associated 
with fluvastatin and thalidomide significantly increased 
survival of pediatric brain stem tumor patients. Tumor 
volume showed a significant reduction accompanied by 
increased quality of life [139]. Thus, given the fact that 
the most evident effect of selective anti-angiogenic agents 
(i.e.  bevacizumab)  is  the  significant  prolonging  of  the 
duration of response obtainable by chemotherapy alone, 
with minimal possible side effects of cytotoxic agents 
given in association metronomic chemotherapy should 
be considered both as novel up-front or maintenance 
treatment in patients with biologically poorly aggressive 
advanced cancer diseases [140].
Overall, metronomic chemotherapy was able to 
induce tumor stabilization and prolong the duration 
of  clinical  benefit,  without  much  associated  toxicity. 
Emerging evidence suggests that metronomic 
chemotherapy could also activate the host immune system 
and potentially induce tumor dormancy [141-143].
cONcLUsIONs AND FUtUrE 
PErsPEctIVEs
While angiogenesis as a hallmark of tumor 
development and metastasis is now a validated target for 
cancer treatment, the overall benefits of anti-angiogenic 
drugs from the perspective of impacting survival have 
left much to desire, endorsing a need for developing 
more effective therapeutic regimens e.g., combining 
anti-angiogenic drugs with established chemotherapeutic 
drugs [144, 145]. There are now several agents that target 
the tumor vasculature through different pathways, either 
by inhibiting formation of the tumor neovasculature or 
by directly targeting the mature tumor vessels. The main 
body of evolving evidence suggests that their effects are 
compounded by their synergistic use with conventional 
chemotherapy rather than individual agents. Anti-
angiogenic drugs such as bevacizumab can bring about a 
transient functional normalization of the tumor vasculature. 
This can have an additive effect when co-administered 
with chemo/radiotherapy. But long term inhibition of 
angiogenesis reduces tumor uptake of co-administered 
chemotherapeutic agents. This underscores the need for 
discovering new targets for anti-angiogenic therapy in 
order to effectively prohibit angiogenesis and circumvent 
mechanisms that contribute to resistance mechanisms that 
emerge with long term use of anti-angiogenic therapies. It 
also warrants a need to define reliable surrogate indicators 
of effectiveness of the anti-angiogenic therapy as well 
as dependable markers for identifying the patients who 
are most likely to benefit from the combination of anti-
angiogenic therapy and conventional chemotherapy. 
Several new frontiers are emerging. New advances 
in understanding endothelial cells, which constitute the 
tumor vasculature, towards developing antiangiogenic 
strategies are one of the important ones [146, 147]. 
Novel cellular targets such as integrins and microRNAs 
and novel treatment options such as possible use of 
pharmaconutrients to modulate angiogenic pathways 
need careful testing and evaluation [148-151]. Finally, 
the administration of these drugs in a metronomic 
schedule is likely to improve the overall response to anti-
angiogenic drugs making it feasible to administer them 
with conventionally toxic chemotherapeutic drugs, thus 
increasing the armamentarium of drug combinations that 
can be employed for treatment.
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